A detailed history of Tcg Crossover Management, LLC transactions in Tarsus Pharmaceuticals, Inc. stock. As of the latest transaction made, Tcg Crossover Management, LLC holds 231,820 shares of TARS stock, worth $10.8 Million. This represents 0.99% of its overall portfolio holdings.

Number of Shares
231,820
Previous 556,317 58.33%
Holding current value
$10.8 Million
Previous $15.1 Million 49.58%
% of portfolio
0.99%
Previous 2.26%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$21.54 - $34.6 $6.99 Million - $11.2 Million
-324,497 Reduced 58.33%
231,820 $7.62 Million
Q2 2024

Aug 14, 2024

SELL
$25.17 - $38.73 $5.98 Million - $9.2 Million
-237,512 Reduced 29.92%
556,317 $15.1 Million
Q1 2024

May 15, 2024

SELL
$19.61 - $39.22 $6.84 Million - $13.7 Million
-349,028 Reduced 30.54%
793,829 $28.9 Million
Q3 2023

Nov 14, 2023

BUY
$14.75 - $24.62 $16.9 Million - $28.1 Million
1,142,857 New
1,142,857 $20.3 Million

Others Institutions Holding TARS

About Tarsus Pharmaceuticals, Inc.


  • Ticker TARS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,658,500
  • Market Cap $1.24B
  • Description
  • Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...
More about TARS
Track This Portfolio

Track Tcg Crossover Management, LLC Portfolio

Follow Tcg Crossover Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tcg Crossover Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Tcg Crossover Management, LLC with notifications on news.